SCHEMBL559268

SCHEMBL559268

O=C(CCCCCCBr)c1ccccc1

nearest known ligand 0.83

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ TDP1 Q9NUW8 3/20 0.83
▸ L3MBTL1 Q9Y468 2/20 0.83
▸ MAPT P10636 2/20 0.83
▸ LMNA P02545 1/20 0.83
▸ HDAC1 Q13547 8/20 0.74
▸ HDAC8 Q9BY41 7/20 0.74
▸ HDAC3 O15379 3/20 0.74
▸ HDAC2 Q92769 3/20 0.74
▸ HDAC4 P56524 2/20 0.74
▸ HDAC7 Q8WUI4 2/20 0.74
▸ HDAC10 Q969S8 2/20 0.74
▸ HDAC11 Q96DB2 2/20 0.74
▸ HDAC6 Q9UBN7 2/20 0.74
▸ HDAC9 Q9UKV0 2/20 0.74
▸ HDAC5 Q9UQL6 2/20 0.74
▸ NPC1 O15118 1/20 0.60
▸ CASP3 P42574 1/20 0.60
▸ RAB9A P51151 1/20 0.60
▸ SENP8 Q96LD8 1/20 0.60
▸ SENP7 Q9BQF6 1/20 0.60

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28609280 1.00 TDP1 (0.83) TDP1L3MBTL1MAPTLMNAHDAC1
SCHEMBL7393801 1.00 TDP1 (0.83) TDP1L3MBTL1MAPTLMNAHDAC1
SCHEMBL7384285 1.00 TDP1 (0.83) TDP1L3MBTL1MAPTLMNAHDAC1
SCHEMBL1308478 0.98 TDP1 (0.79) TDP1L3MBTL1MAPTLMNAHDAC1
SCHEMBL2116192 0.94 TDP1 (0.72) TDP1L3MBTL1MAPTLMNAHDAC1
SCHEMBL9057671 0.91 TDP1 (1.00) TDP1L3MBTL1MAPTLMNAHDAC1
SCHEMBL27516050 0.91 TDP1 (1.00) TDP1L3MBTL1MAPTLMNAHDAC1
SCHEMBL8519287 0.91 TDP1 (1.00) TDP1L3MBTL1MAPTLMNAHDAC1
SCHEMBL7068671 0.89 TDP1 (0.95) TDP1L3MBTL1MAPTLMNAHDAC1
SCHEMBL9352420 0.85 HDAC1 (1.00) TDP1L3MBTL1MAPTLMNAHDAC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9110069-B2 Luminescent compounds SETA BIOMEDICALS, LLC (US) 2015-08-18 — — US disclosed
EP-2129788-B1 LUMINESCENT COMPOUNDS SETA BIOMEDICALS LLC (US) 2014-09-03 — — EP disclosed
US-20140086844-A1 LUMINESCENT COMPOUNDS SETA BIOMEDICALS, LLC (US) 2014-03-27 — — US disclosed
US-8642014-B2 Luminescent compounds SETA BIOMEDICALS, LLC (US) 2014-02-04 — — US disclosed
US-8552027-B2 Luminescent compounds SETA BIOMEDICALS, LLC (US) 2013-10-08 — — US disclosed
US-20120035346-A1 LUMINESCENT COMPOUNDS SETA BIOMEDICALS, LLC 2012-02-09 — — US disclosed
US-20100266507-A1 LUMINESCENT COMPOUNDS SETA BIOMEDICALS, LLC 2010-10-21 — — US disclosed
WO-2010083471-A1 LUMINESCENT COMPOUNDS SETA BIOMEDICALS, LLC (US) 2010-07-22 — — WO disclosed
EP-2129788-A2 LUMINESCENT COMPOUNDS Seta Biomedicals, LLC (US) 2009-12-09 — — EP disclosed
US-7411068-B2 Luminescent compounds SETA BIOMEDICALS, LLC 2008-08-12 — — US disclosed
WO-2008094637-A2 LUMINESCENT COMPOUNDS SETA BIOMEDICALS. LLC (US) 2008-08-07 — — WO disclosed
US-20070281363-A1 Reporter molecules based on squaric, croconic, and/or rhodizonic acid; photoluminescence Terpetschnig, Ewald (US) 2007-12-06 — — US disclosed
US-7250517-B2 Luminescent compounds Terpetschnig, Ewald A. (US) 2007-07-31 — — US disclosed
US-20050202565-A1 Luminescent compounds SETA BIOMEDICALS, LLC 2005-09-15 — — US disclosed
US-20040166515-A1 Luminescent compounds TERPETSCHNIG, EWALD A. 2004-08-26 — — US disclosed
US-5864039-A THERAPEUTIC TREATMENT OF VARIOUS GASTROINTESTINAL DISEASES, CENTRAL NERVOUS DISORDERS, CARDIOVASCULAR DISORDERS, URINARY DISEASES, UROGENITAL DISORDERS YOSHITOMI PHARMACEUTICAL INDUSTRIES, LTD. (JP) 1999-01-26 — — US disclosed
EP-0873990-A1 BENZOIC ACID COMPOUNDS AND MEDICINAL USE THEREOF YOSHITOMI PHARMACEUTICAL INDUSTRIES, LTD. (JP) 1998-10-28 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100266507-A1 LUMINESCENT COMPOUNDS SQLE, COASY, ZKSCAN2 TDP1 4554/4885L3MBTL1 398/4885MAPT 4099/4885
US-20140086844-A1 LUMINESCENT COMPOUNDS PHOSPHO1, PGLS, PFAS TDP1 1854/4885L3MBTL1 862/4885MAPT 1439/4885
US-20120035346-A1 LUMINESCENT COMPOUNDS PHOSPHO1, PGLS, PFAS TDP1 2133/4885L3MBTL1 791/4885MAPT 1265/4885
US-20040166515-A1 Luminescent compounds RORC, NR2E3, RORB TDP1 4285/4885L3MBTL1 929/4885MAPT 4542/4885
US-20070281363-A1 Reporter molecules based on squaric, croconic, and/or rhodizonic acid; photoluminescence SPR, SRRT, SQLE TDP1 4192/4885L3MBTL1 2272/4885MAPT 3790/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback